Outlook Therapeutics Bolsa (NASDAQ: OTLK)

Últimas noticias sobre Outlook Therapeutics (NASDAQ:OTLK) Bolsa

OUTLOOK THERAPEUTICS INC

Outlook Therapeutics

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Descubre qué acciones sobrevendidas del sector salud tienen un RSI por debajo de 30 y podrían estar infravaloradas.

3 acciones estadounidenses de atención médica que podrían despegar este mes

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics Inc

WIIM

OKLO

Oklo shares are trading higher after Wedbush raised its price target on the stock from $45 to $55 and maintained an Outperform rating.

After careful consideration, Exchange Traded Concepts, LLC, the Fund's investment adviser has recommended, and the Board of Trustees of Exchange Traded Concepts Trust has approved, the termination and liquidation of the Range Global Offshore Oil Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OFOS#NYSE">OFOS</a>) pursuant to the terms of a Plan of&nbsp;Liquidation. Accordingly, the Fund is expected to cease operations and liquidate on or about June 20, 2025 (the "Liquidation&nbsp;Date").
The Fund will be closed to orders for new creation units on June 16, 2025, and the last day of trading of the Fund's shares on the NYSE Arca, Inc. will be on or about June 17, 2025. From June 17, 2025 through the last day of trading, shareholders may only be able to sell their shares to certain broker-dealers, and there is no assurance that there will be a market for Fund shares during that time period. Customary brokerage charges may apply to such transactions. From the last day of trading through the Liquidation Date, shareholders will not be able to purchase or sell shares in the secondary market.

OFOS

Exchange Traded Concepts Approves Termination And Liquidation Of Range Global Offshore Oil Services ETF; Fund Expected To Cease Operations And Liquidate On Or About June 20, 2025

<ul>
<li>Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity</li>
<li>Opinion follows FDA approval and MHRA conditional marketing authorisation</li>
<li>European Commission (EC) decision on conditional marketing authorization application (MAA) expected within approximately two months</li>
</ul>
Autolus Therapeutics plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended European Commission (EC) approval of obecabtagene autoleucel (obe-cel) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).
"This positive CHMP opinion is a welcome advancement for physicians and patients in&nbsp;Europe, faced with treating r/r adult B-ALL patients with a poor prognosis,"&nbsp;said Dr. Claire Roddie, MD, PhD, FRCPath,&nbsp;Lead Investigator&nbsp;of the FELIX study and Associate Professor of Haematology at the University College London (UCL) Cancer Institute. "Obe-cel's combination of favorable tolerability and potential long-term outcomes could offer an important new treatment option for patients in the EU."
The CHMP recommendation was based on the results of the FELIX study, an open-label, multi centre, single arm study in adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia. The results were published in the New England Journal of Medicine in November 20241. In the pivotal cohort of patients, (cohort IIA (n=94)), the Complete Response/Complete Response with Incomplete Haematological Recovery (CR/CRi) for patients who received at least one infusion of obecabtagene autoleucel was 76.6%. Median response duration for all infused patients was 21.2 months. Median event-free survival (EFS) was 11.9 months and the estimated 6- and 12-month event-free survival rates were 65.4% and 49.5%, respectively.
The most common non-laboratory Grade&nbsp;3 or higher adverse reactions were infections-pathogen unspecified (32%), febrile neutropenia (24%) and bacterial infectious disorders (11%). Cytokine release syndrome developed in 87 of the 127 patients (68.5%), with events of grade 3 or higher in three patients (2.4%). Immune effector cell-associated neurotoxicity syndrome developed in 29 of the 127 patients (22.8%), with grade 3 or higher occurring in nine patients (7%).
"This positive opinion from the CHMP highlights the significant unmet need and importance of effective treatment options for adult r/r B-ALL,"&nbsp;said Dr. Christian Itin, Chief Executive Officer of Autolus. "With FDA approval received in November 2024 and an MHRA conditional marketing authorization received in April 2025, we are on our way to bringing this therapy to patients in need globally."
Obe-cel is an autologous CD19 CAR T cell therapy with a proprietary CD19 CAR, invented by a team led by Dr. Martin Pule, at University College London, along with collaborators at Great Ormond Street Hospital and University College London Hospital. The CAR is designed to have a fast "off-rate" which mimics physiological T-cell receptor interactions2.
ALL is an aggressive type of blood cancer that can also involve the lymph nodes, spleen, liver, central nervous system and other organs. In Europe, there are approximately 6,0002 new cases of ALL diagnosed every year. In frontline treatment for adult B-ALL, up to 50% of patients will ultimately relapse3. Survival rates remain very poor in adult patients with r/r ALL, with median overall survival of eight months with conventional treatments4, and the standard-of-care treatment can trigger severe toxicities5.
The positive CHMP opinion is a scientific recommendation for marketing authorization, serving as a basis for the EC's final decision on Autolus' MAA for obe-cel for adult r/r B-ALL patients. The EC is expected to make a decision following CHMP recommendation, and the decision will apply to all 27 European Union Member States, Iceland, Norway and Liechtenstein. Obe-cel is currently approved by the U.S. Food and Drug Administration (FDA) (Nov 8, 2024), and authorized by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) (April 25, 2025).

Biotech

General

AUTL

Autolus Therapeutics Announces Positive CHMP Opinion For Obecabtagene Autoleucel for Adult Patients With Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

MNSO

MINISO Group shares are trading lower after the company reported worse-than-expected Q1 sales results and a year-over-year decrease in Q1 EPS results.

Citigroup analyst Karen Holthouse initiates coverage on US Foods Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) with a Buy rating and announces Price Target of $95.

Price Target

Initiation

Analyst Ratings

USFD

Citigroup Initiates Coverage On US Foods Hldg with Buy Rating, Announces Price Target of $95

GILD

Gilead Sciences Announces Topline Results From Phase 3 ASCENT-03 Study Of Trodelvy Met Its Primary Endpoint

Maybe you're living the good life now—grocery delivery, takeout on repeat, the kind of spending that doesn't require checking your bank app first. Or maybe you're playing the long game—budgeting, investing, skipping the daily lattes—hoping it all pays off when retirement rolls around.
Either way, the goal's the same: to retire comfortably, maybe even with a taste of the upper class.
But what does that actually take? More specifically, how much does the average <a href="https://www.benzinga.com/personal-finance/25/05/45234639/are-you-upper-class-heres-the-net-worth-you-need-in-your-50s">upper-class household</a> really have set aside for retirement?
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
<h2 class="wp-block-heading">What Does "Upper Class" Even Mean?</h2>
It's not just about income—though that's part of it. According to <a href="https://www.pewresearch.org/race-and-ethnicity/2024/05/31/the-state-of-the-american-middle-class/">Pew Research</a>, an upper-class household of three earns at least $256,920. But income alone won't carry you through retirement. That's where net worth—and retirement savings—take over.
A <a href="https://www.nytimes.com/interactive/2019/08/12/upshot/are-you-rich-where-does-your-net-worth-rank-wealth.html">New York Times analysis</a> shows upper-class families typically have a 3:1 wealth-to-income ratio, meaning that $256,000 income translates to around $770,760 in net worth.
And according to the <a href="https://www.federalreserve.gov/econres/scfindex.htm">Federal Reserve's Survey of Consumer Finances</a>:
<ul class="wp-block-list">
<li>The top 10% of U.S. households hold a median net worth of $2.7 million.</li>
<li>The 75th to 89.9th percentile sits closer to $790,000. </li>
</ul>
So whether you define "upper class" by income or wealth, the <a href="https://www.benzinga.com/personal-finance/25/02/43539942/are-you-rich-heres-what-americans-think-you-need-to-be-considered-wealthy-2">bar is high—and rising</a>.
<h2 class="wp-block-heading">Here's What They've Actually Saved for Retirement</h2>
Net worth can include a lot—your house, your brokerage account, maybe even a chunk of that side business your cousin swears is "about to blow up." But when it comes to what's specifically earmarked for retirement, the <a href="https://www.federalreserve.gov/publications/2023-economic-well-being-of-us-households-in-2022-retirement-investments.htm">numbers start to look a little more grounded</a>.
<ul class="wp-block-list">
<li>The top 10% have a median retirement savings of $900,000.</li>
<li>The next tier down—the 75th to 89.9th percentile—comes in at just $269,000. </li>
</ul>
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
That's a big drop, and a good reminder: being "upper class" doesn't always mean you're <a href="https://www.benzinga.com/personal-finance/24/10/41127976/are-you-a-rich-retiree-heres-the-net-worth-and-income-you-need-to-be-in-the-top-10">sitting on millions</a> in a retirement account.
Put that next to the median U.S. household, which has about $87,000 saved, and the picture gets clearer. Overall, the average upper-class retirement nest egg likely falls somewhere between $400,000 and $500,000—solid, for sure, but maybe not as sky-high as you'd assumed.
<h2 class="wp-block-heading">What Puts the Wealthy Ahead?</h2>
It's not just bigger paychecks—it's different habits. The wealthiest 20% tend to approach retirement planning like a long game, not a last-minute scramble. Here's what they often get right:
<ol class="wp-block-list">
<li>They save like it's a bill For them, contributing to retirement isn't optional—it's automatic. Pay comes in, savings go out. No debate. </li>
<li>They invest early—and stay in They don't try to time the market. They buy, hold, and let compounding do its quiet magic. </li>
<li>They make the tax code work for them  Roth IRAs, 401(k) matches, HSAs—they know the tools and use them. Every little tax break adds up. </li>
<li>They get advice instead of winging it They're not scrolling Reddit for retirement tips. They call someone with a license and a strategy. </li>
<li>They plan for the life they want—not just the bills they'll owe </li>
</ol>
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
<h2 class="wp-block-heading">Want To Catch Up? Here's Where To Start</h2>
If you're not where you planned to be, don't panic. These moves can help you build your own retirement cushion:
<ul class="wp-block-list">
<li>Start where you are: Even small contributions add up over time. </li>
<li>Max out your employer match: Free money? Always say yes. </li>
<li>Open an IRA: Traditional or Roth, it's another place to grow your savings tax-advantaged. </li>
<li>Boost your savings rate: Every raise is an opportunity. </li>
<li>Use catch-up contributions: If you're 50+, take advantage of higher limits. </li>
</ul>
The upper class isn't coasting through retirement on vibes—they're bringing real savings to the table. Somewhere between $400,000 and $900,000, to be exact.
If you're living well now, think of retirement like the sequel: it should live up to the original. But it won't happen by accident. <a href="https://www.benzinga.com/money/are-you-rich">It takes planning, habit, and a little bit of discipline</a>—right alongside the Amazon boxes and sushi orders.
Read Next:
<ul class="wp-block-list">
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a> </li>
</ul>
Image: Shutterstock

Personal Finance

Do You Have An 'Upper Class' Nest Egg? Here's What The Top 20% Have Saved For Retirement — Hint, It's Less Than You'd Think

Autolus Therapeutics Announces Positive CHMP Opinion For Obecabtagene Autoleucel In Adult Patients With Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Mark Yusko, the founder and CIO of Morgan Creek Capital, believes the ongoing Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rally is <a href="https://www.benzinga.com/money/bitcoin-price-prediction">far from over</a>.
What Happened: Speaking as Bitcoin surpassed a new all-time high near $111,000, Yusko said the asset's upward trajectory is backed by deep structural forces and a fundamental shift in how the global economy treats money.
"This idea that we should be surprised that we keep making all-time highs? Of course we're going to make new all-time highs," Yusko <a href="https://www.youtube.com/live/z7qkIRX1GJQ">said</a>, pointing to the rapid devaluation of fiat currencies. "We printed 80% of all the dollars that ever existed in the last five years."
Unlike traditional assets like stocks and bonds, Yusko emphasized that Bitcoin's performance is not linked to GDP growth or inflation. 
"Bitcoin prices are determined by the technology itself, by adoption, particularly among young people, and by changes in fiat," he said, reiterating that Bitcoin is "so not correlated" with other asset classes over the long term.
Yusko called Bitcoin a modern form of money, superior to gold due to its portability and divisibility. 
"One Bitcoin is one Bitcoin," he added, highlighting that its value is not diluted over time. "It's like an ounce of gold. A single ounce of gold is still a single ounce of gold."
The bullish sentiment was echoed by other guests on the show. 
Dan, a technical analyst from The Chart Guys, noted that a golden cross, when the 50-day moving average crosses above the 200-day, just occurred, which has historically preceded parabolic advances. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45570094/anthony-scaramucci-says-thin-supply-is-driving-bitcoin-to-new-all-time-highs">Anthony Scaramucci Says Thin Supply Is Driving Bitcoin To New All-Time Highs</a>
"This asset wants to go," Dan said, describing current price momentum as "ideal."
While some observers are cautious, recalling previous failed breakouts, Yusko said the macroeconomic landscape supports further gains. 
He cited treasury auctions failing, uncontrolled interest rates in Japan, and ongoing inflation in Western economies as signals of systemic weakness in fiat-based systems. 
"There's a point at which a country loses control and you get hyperinflation," he warned.
Despite differing opinions on the immediate threat of hyperinflation, Yusko and fellow panelist Yago agreed that the only politically viable way out of the current debt trap is through currency devaluation. 
"You can't pay it back. You can't restructure it. You can't default on it. So you devalue it," Yusko said.
What&#8217;s Next: For Yusko, Bitcoin is not just an investment, it's protection against what he called the "dictator playbook": wealth concentration, inflation, and the erosion of civil liberties through financial repression.
He pointed out how other nations have already seen Bitcoin reach record highs locally due to collapsing currencies, including Venezuela, Turkey, and Argentina.
"Bitcoin is better than gold," Yusko said. "It's money that doesn't rely on the liabilities of governments and it's the foundation of a new financial system that's already here."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45567511/no-one-can-shut-down-bitcoin-says-impossible-cloud-founder">&#8216;No One Can Shut Down Bitcoin,&#8217; Says Impossible Cloud Founder</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Rally Has Room To Run, Says Morgan Creek's Mark Yusko

Citigroup analyst Karen Holthouse initiates coverage on Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) with a Neutral rating and announces Price Target of $78.

Citigroup Initiates Coverage On Sysco with Neutral Rating, Announces Price Target of $78

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he <a href="https://www.benzinga.com/news/large-cap/25/05/45490992/vertiv-develops-power-solutions-in-sync-with-nvidias-ai-roadmap">likes Vertiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>)</a>.
As per the recent news, on Monday, Vertiv announced its strategic alignment with Nvidia Corp.‘s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) vision for AI data centers, specifically the deployment of 800 VDC power architectures. Anticipating the demands of future AI deployments, including the NVIDIA Kyber and Rubin Ultra platforms, Vertiv's comprehensive 800 VDC power portfolio is slated for release in the second half of 2026.
Cramer said no to Medical Properties Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>), noting that there is &#8220;too much risk.&#8221;
Supporting his view, Medical Properties Trust reported a quarterly FFO of 14 cents per share on May 1, which missed the analyst consensus estimate of 15 cents per share. The company also reported quarterly sales of $223.80 million, which missed the analyst consensus estimate of $229.81 million.
The Mad Money host recommended owning Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) for the long term.
Lending support to his choice, Nucor posted better-than-expected earnings for the first quarter on April 28. The company reported quarterly earnings of 77 cents per share, which beat the analyst consensus estimate of 64 cents per share. The company reported quarterly sales of $7.83 billion, which beat the analyst consensus estimate of $7.23 billion.
Price Action:
<ul class="wp-block-list">
<li>Vertiv shares gained 0.6% to settle at $104.20 on Thursday.</li>
<li>Medical Properties Trust shares declined 1.3% to close at $4.56 during the session.</li>
<li>Nucor shares fell 0.9% to settle at $110.69 on Thursday.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45562909/top-2-financial-stocks-that-may-keep-you-up-at-night-in-may">Top 2 Financial Stocks That May Keep You Up At Night In May</a></li>
</ul>
Photo: Shutterstock

Media

NVDA

Jim Cramer Says Medical Properties Trust Has 'Too Much Risk,' Likes This Industrial Stock

Citigroup analyst Karen Holthouse initiates coverage on Performance Food Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) with a Buy rating and announces Price Target of $121.

PFGC

Citigroup Initiates Coverage On Performance Food Gr with Buy Rating, Announces Price Target of $121

President Donald Trump&#8217;s threat to impose a sweeping 50% tariff on all European Union imports starting June 1 sparked a broad selloff across European markets Friday, triggering fears of a transatlantic trade war just as global <a href="https://www.benzinga.com/topic/tariffs">growth faces renewed pressure.</a>
In a post on Truth Social, Trump said the EU&#8217;s "powerful Trade Barriers, VAT Taxes, ridiculous Corporate Penalties, Non-Monetary Trade Barriers, Monetary Manipulations, unfair and unjustified lawsuits against American Companies" were to blame for an annual trade deficit exceeding $250 billion, which he called "totally unacceptable."
The proposed tariff would exempt goods manufactured in the United States, potentially creating sharp distortions for EU-based exporters and global supply chains.
<h3 class="wp-block-heading">European Benchmarks Tumble</h3>
The fallout was immediate in markets. The Euro STOXX 50 index – as closely tracked by the iShares MSCI Eurozone ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EZU#NYSE">EZU</a>) – dropped 3%, Italy's FTSE MIB sank 2.9%, France's CAC 40 lost 2.6% and Spain's IBEX 35 fell 2.2%. 
Germany's DAX, as tracked by the iShares MSCI Germany Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWG#NYSE">EWG</a>), which is home to many export-heavy firms, slid 2.3%.
Financial stocks bore the brunt of the decline, with Deutsche Bank AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) falling 6.1%, Société Générale SA (OTCPK: SCGLY) down 5.3% and Banco Bilbao Vizcaya Argentaria SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBVA#NYSE">BBVA</a>) sliding 5%.
 Industrial and luxury exporters also came under heavy pressure, including Bayerische Motoren Werke AG (OTCPK: BMWYY), or BMW (−4.5%), UniCredit SpA (OTCPK: UNCRY) (−4.5%) and EssilorLuxottica SA (OTCPK: ESLOY) (−4.2%).
<h3 class="wp-block-heading">Export Exposure To US Trade Is Key</h3>
The tariff threat has placed a spotlight on European companies heavily reliant on U.S. revenues.
In Germany, Adidas AG (OTCPK: ADDYY) derives roughly a third of its revenue from the United States, while SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) generates about 40% of its turnover from North America. 
Chipmaker Infineon Technologies AG (OTCPK: IFNNY) is also significantly exposed due to its automotive and electronics customers.
French luxury and tech firms are equally at risk. LVMH Moët Hennessy Louis Vuitton SE (OTCPK: LVMUY) earns close to 25% of its revenue in the U.S., while Dassault Systèmes SE (OTCPK: DASTY) has a strong footprint in North American enterprise software. Hermès International SA (OTCPK: HESAY) pulls about 20-25% of its sales from the American market.
Italian brands like Ferrari NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>), with over 30% of sales from the U.S., and EssilorLuxottica SA (OTCPK: ESLOY), which owns Oakley and Ray-Ban, are also vulnerable. 
In the Netherlands, tech heavyweight ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) earns about 20-25% of revenue from the U.S., and Koninklijke Philips NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) maintains a major healthcare business across North America.
<h3 class="wp-block-heading">EU Retaliation Risk Grows For US Stocks</h3>
For U.S. corporations with heavy exposure to Europe—particularly in tech, autos, agriculture and aviation—the economic consequences could be significant if the European Union responds in kind.
The 2018 EU countermeasures to Trump&#8217;s steel tariffs included duties on motorcycles, bourbon and orange juice—strategic hits on U.S. swing-state exports.
EU officials may also revisit tech taxation disputes, where U.S. firms like Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) are already under regulatory scrutiny.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45584696/trump-threatens-tim-cook-to-manufacture-iphones-in-the-us-or-face-at-least-25-tariffs">Trump Threatens Tim Cook To Manufacture iPhones In US Or Face &#8216;At Least 25%&#8217; Tariffs: AAPL Stock Slides Over 3% In Premarket </a></li>
</ul>
Photo Courtesy: Joshua Sukoff On Shutterstock.com

Analyst Color

Macro Economic Events

Sector ETFs

Eurozone

Econ #s

Economics

ETFs

AAPL

ADDYY

ASML

BBVA

BMWYY

DASTY

ESLOY

GOOGL

HESAY

IFNNY

LVMUY

MSFT

RACE

SCGLY

UNCRY

Trump Tariff Threat Hits Europe: Stocks Sink As 50% Duties Loom

Analog Devices shares are trading lower after Benchmark cut its price target on the stock from $275 to $260. Also, Needham reiterated a Hold rating.

Jim Lebenthal of Cerity Partners named Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) as his final trade on CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/22/final-trades-delta-air-lines-mercadolibre-toast-and-the-iye.html">Halftime Report Final Trades</a>,&#8221; adding that people are flying and growth estimates <a href="https://www.benzinga.com/quote/DAL/analyst-ratings" target="_blank" rel="noopener">will</a><a href="https://www.benzinga.com/quote/DAL/analyst-ratings"> start going back higher</a>.
UBS analyst Thomas Wadewitz supported his view on Monday by upgrading Delta Air Lines from Neutral to Buy and raising the price target from $46 to $66.
Shannon Saccocia, chief investment officer of NB Private Wealth, said the iShares U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYE#NYSE">IYE</a>) is undervalued because it is priced in with a lot of negative news.
Supporting her view, Paycom Software, on May 7, reported better-than-expected first-quarter earnings and sales.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joseph M. Terranova, senior managing director for Virtus Investment Partners, said MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) is the best consumer discretionary stock.
Adding support to his choice, MercadoLibre, on May 7, reported quarterly earnings of $9.74 per share which beat the analyst consensus estimate of $8.03 per share. The company reported quarterly sales of $5.93 billion which beat the analyst consensus estimate of $5.51 billion.
Joshua Brown, CEO of Ritholtz Wealth Management, named Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) his final trade.
Supporting his view, BMO Capital analyst Rufus Hone maintained Toast with an Outperform rating on May 12 and raised the price target from $44 to $45.
Price Action:
<ul class="wp-block-list">
<li>Delta Air Lines shares gained 0.5% to close at $48.50 on Thursday.</li>
<li>Toast shares fell 0.4% to close at $42.68 on Thursday.</li>
<li>MercadoLibre gained 0.2% to settle at $2,606.01 during Thursday's session.</li>
</ul>
Check This Out:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45562909/top-2-financial-stocks-that-may-keep-you-up-at-night-in-may"> Top 2 Financial Stocks That May Keep You Up At Night In May</a></li>
</ul>
Photo: Shutterstock

iShares Dow Jones US Energy Sector Index Fund

MELI

TOST

Toast, Delta Air Lines, MercadoLibre And More On CNBC's 'Final Trades'

Maxim Group analyst Jason McCarthy downgrades Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) from Buy to Hold.

Downgrades

CTXR

Maxim Group Downgrades Citius Pharmaceuticals to Hold

IMNN

IMUNON shares are trading higher after the company announced new data from its Phase 2 OVATION 2 Study of IMNN-001.

USA Building Permits For April 1.422M Vs 1.412M Est.; 1.467M Prior

USA Building Permits (MoM) For April -4.0% Vs -4.7% Est.; 0.5% Prior

Leerink Partners analyst Joseph Schwartz upgrades Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) from Market Perform to Outperform and raises the price target from $4 to $12.

Upgrades

FULC

Leerink Partners Upgrades Fulcrum Therapeutics to Outperform, Raises Price Target to $12

Management

Press Releases

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics® Participates in Virtual Investor "What This Means" Segment

Earnings

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Events

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

Outlook Therapeutics® Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Health Care

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

IPOs

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

AKTX

AMIX

AREC

CNSP

HURA

NVNO

PALI

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Biomea Fusion

Celularity

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

ImmuCell

Immuneering Corporation - Class A Common Stock

Immuneering

Opus Genetics

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

MAIA Biotechnology

Metagenomi

OKYO Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

Renovaro

Repare Therapeutics

Serina Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Ascendiant Capital

HC Wainwright & Co.

Chardan Capital

Guggenheim

BTIG

Comments

Outlook Therapeutics

Noticias

Últimas noticias sobre Outlook Therapeutics (NASDAQ:OTLK) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL